Study Identifies Standard Multiple Myeloma Treatment
The CEPHEUS trial highlights improved efficacy for DVRd in transplant-ineligible multiple myeloma patients.
Updated on Oct. 28, 2026 in Cancer
Live Poll
Should new cancer drug combinations become the standard of care based on initial trial results?
Published on September 25, 2026, in the Journal of Clinical Oncology, the CEPHEUS study indicates that DVRd is a standard treatment for transplant-ineligible patients with multiple myeloma. Researchers found that this regimen significantly improves sustained minimal residual disease negativity compared to traditional therapies.
Why it matters
This study addresses the critical challenge of treating patients who are ineligible for transplants by identifying a more effective pharmaceutical approach. The findings provide a clearer clinical pathway for improving long-term outcomes in a vulnerable patient population.
In the CEPHEUS trial of 289 patients, those receiving DVRd achieved a 60.4% MRD negativity rate at 10-5 for 12 months, compared to 39.3% for the VRd group. The hazard ratio for progression or death was 0.51 for patients treated with DVRd.
The players
Journal of Clinical Oncology
This peer-reviewed medical journal publishes significant research in oncology and serves as the official publication of the American Society of Clinical Oncology.
CEPHEUS study
This clinical trial program evaluates the safety and efficacy of novel treatment regimens for patients diagnosed with multiple myeloma.
The details
The study assigned 144 patients to the DVRd group and 145 to the VRd group, with a median follow-up period of 58.7 months. While DVRd showed superior efficacy, 93.1% of patients in that group experienced grade 3 or worse adverse events, most commonly neutropenia, infection, and thrombocytopenia.
Timeline
September 25, 2026: The study was published online in the Journal of Clinical Oncology.
Health Landscape
The findings from the CEPHEUS study represent a shift in the standard of care for multiple myeloma by validating DVRd as a highly effective regimen. This development marks a significant milestone in evolving treatment protocols for patients unable to undergo transplantation.
Patients and healthcare providers can utilize these results to discuss more effective treatment options for those ineligible for transplants. However, patients should be aware of the increased frequency of grade 3 adverse events, such as neutropenia, when considering the DVRd regimen.
The takeaway
This study establishes DVRd as a superior option for improving MRD negativity in transplant-ineligible multiple myeloma patients. Clinicians and patients should balance these efficacy gains against the higher incidence of severe side effects documented in the trial.
Further reading
Learn more about the latest research and standard of care developments on the Cancer page.
More information
View the comprehensive trial details in the CEPHEUS study registry record.
Source note: This article includes information reported by Cancer Therapy Advisor.
Live Poll
Should new cancer drug combinations become the standard of care based on initial trial results?
